Related Experiment Video
Updated: Jul 3, 2026
Combining QD-FRET and Microfluidics to Monitor DNA Nanocomplex Self-Assembly in Real-Time
Published on: August 26, 2009
Microfluidics-Assembled Nanovesicles for Nucleic Acid Delivery
Xuanyu Li1,2, Zhiliang Qin2, Saijie Wang2
1Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 510182 Guangdong, P. R. China.
Microfluidic technology enables precise, one-step production of nanovesicles for drug delivery, improving reproducibility and enabling multi-drug codelivery. Innovations address cytotoxicity and enhance control over nanovesicle properties for clinical applications.
Area of Science:
- Biotechnology and Nanotechnology
- Materials Science
- Drug Delivery Systems
Background:
- Conventional nanovesicle production methods suffer from batch-to-batch variability due to complex intermediate steps.
- Nanovesicles are promising for drug and nucleic acid delivery but face challenges with cytotoxicity and in vivo stability.
- Positively charged nanovesicles, often used for nucleic acid delivery, exhibit significant cytotoxicity.
Purpose of the Study:
- To highlight the advantages of microfluidic technology for reproducible nanovesicle production.
- To discuss strategies for mitigating nanovesicle cytotoxicity for enhanced clinical feasibility.
- To explore microfluidic control over nanovesicle properties like size, rigidity, and morphology.
Main Methods:
- Utilized microfluidic platforms for one-step, streamlined assembly of nanovesicles encapsulating diverse therapeutic agents.
- Investigated charge-shifting materials and surface modifications to reduce nanovesicle cytotoxicity at physiological pH.
- Manipulated flow rates and interfacial water layers within microfluidic channels to control particle size and potentially rigidity.
Main Results:
- Microfluidics enables precise control over nanovesicle size and encapsulation efficiency, improving batch-to-batch reproducibility.
- Charge-shifting strategies show promise in reducing nanovesicle cytotoxicity, enhancing clinical potential.
- Automation through advanced microfluidic designs improves the integration of assembly and surface modification.
Conclusions:
- Microfluidic technologies offer a powerful platform for developing multifunctional nanovesicles for precision medicine.
- Overcoming challenges in cytotoxicity, scalability, and reproducibility is key for clinical translation.
- Continued innovation in chip design, materials, and automation will advance microfluidic applications in therapeutic delivery.
